45 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting thea
Universit£
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.
Philipps-Universit£T Marburg
Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.
Technische Universit£T M£Nchen
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.
Technische Universit£T M£Nchen
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrinaVß3.
Universit£
Camptothecins in tumor homing via an RGD sequence mimetic.
Sigma-Tau Industrie Farmaceutiche Riunite
Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.
Department of Organic Chemistry Ugo Schiff University of Firenze Via Della Lastruccia 13
Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.
Universit£
Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Johnson & Johnson Pharmaceutical Research and Development
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.
Universit£
Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.
3-Dimensional Pharmaceuticals
Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.
University of Florence
Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.
Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.
Jerini
Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.
Pfizer
Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.
Pfizer
Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.
Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
Pfizer
Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.
Johnson and Johnson Pharmaceutical Research & Development
Sortase A-mediated cyclization of novel polycyclic RGD peptides for ?
Hefei Normal University
1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.
Johnson & Johnson Pharmaceutical Research & Development
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.
Pfizer
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Glaxosmithkline
Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones.
Basf
Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.
Institut De Recherches Servier
Dual antagonists of ?5?1/?v?1 integrin for airway hyperresponsiveness.
University of California San Francisco
Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.
Merck
New ?-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
University of Bologna
Novel cilengitide-based cyclic RGD peptides as ?v?
Division of Organic Chemistry Csir-National Chemical Laboratory (Ncl)
Selective Targeting of Integrin ?v?8 by a Highly Active Cyclic Peptide.
Technische Universit£T M£Nchen
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Smithkline Beecham Pharmaceuticals
Profile of a Highly Selective Quaternized Pyrrolidine Betaine ?
Glaxosmithkline Medicines Research Centre
In silico studies, synthesis and binding evaluation of substituted 2-pyrrolidinones as peptidomimetics of RGD tripeptide sequence.
Universit£
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
University of Bradford
Structure Activity Relationships of ?v Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents.
University of Nottingham
Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.
Telios Pharmaceuticals
Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic ?
University of Strathclyde